@article {Mikhaylov2021.03.03.21252855, author = {Evgeny N. Mikhaylov and Tamara A. Lyubimtseva and Aleksandr D. Vakhrushev and Dmitry Stepanov and Dmitry S. Lebedev and Elena Yu. Vasilieva and Alexandra O. Konradi and Evgeny V. Shlyakhto}, title = {Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study}, elocation-id = {2021.03.03.21252855}, year = {2021}, doi = {10.1101/2021.03.03.21252855}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Bromhexine hydrochloride has been suggested as a TMPRSS2 protease blocker that precludes the penetration of SARS-CoV-2 into cells. We aimed to assess the preventive potential of regular bromhexine hydrochloride intake for COVID-19 risk reduction in medical staff actively involved in the evaluation and treatment of patients with confirmed or suspected SARS-CoV-2 infection.Methods In a single-center randomized open-label study, medical staff managing patients with suspected and confirmed COVID-19 were enrolled and followed up for 8 weeks. The study began at the initiation of COVID-19 management in the clinic. The study was prematurely terminated after the enrollμent of 50 participants without a history of SARS-CoV-2 infection: 25 were assigned to bromhexine hydrochloride treatment (8 mg 3 times per day), and 25 were controls. The composite primary endpoint was a positive nasopharyngeal swab polymerase chain reaction (PCR) test for SARS-CoV-2 or signs of clinical infection within 28 days and at week 8. Secondary endpoints included: time from the first contact with a person with COVID-19 to the appearance of respiratory infection symptoms; the number of days before a first positive SARS-CoV-2 test; the number of asymptomatic participants with a positive nasopharyngeal swab test; the number of symptomatic COVID-19 cases; adverse events.Results The rate of the combined primary endpoint did not differ significantly between the active treatment group (2/25 [8\%]) and control group (7/25 [28\%]); P=0.07. A fewer number of participants developed symptomatic COVID-19 in the treatment group compared to controls (0/25 vs 5/25; P = 0.02).Conclusion Although the study was underpowered, it showed that Bromhexine hydrochloride prophylaxis was associated with a reduced rate of symptomatic COVID-19. The prophylactic treatment was not associated with a lower combined primary endpoint rate, a positive swab PCR test, or COVID-19. (ClinicalTrials.gov number, NCT04405999)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04405999Funding StatementThe study was supported by the State assignment $\#$А18-118042390114-2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Almazov National Medical Research Centre ethics committee (protocol $\#$0105-20-02С from May 12, 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll date are available upon request to the authors}, URL = {https://www.medrxiv.org/content/early/2021/05/29/2021.03.03.21252855}, eprint = {https://www.medrxiv.org/content/early/2021/05/29/2021.03.03.21252855.full.pdf}, journal = {medRxiv} }